Avery Pharmaceuticals starts commercial production of unit at Sanand

The plant is a dedicated for manufacturing of Mouth dissolving strip.

Lynparza with Bevacizumab demonstrates survival in certain patients with first-line advanced ovarian cancer

The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients

Vandemark gets investment from SK Capital with Comvest partners

SK Capital’s investment will serve as a catalyst for a new strategic direction as the Company seeks to deepen and expand its presence in fine chemistries for the global life science market.

Health Secretary addresses workshop on 'Roadmap to Strengthen Public Health Preparedness and Response Capabilities of Points of Entry (PoEs) in India'

India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency

World’s first intra nasal vaccine iNCOVACC from Bharat Biotech receives approval

iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy

Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital

In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery

Artemis Hospitals opens new centre Daffodils by Artemis in Jaipur

Daffodils by Artemis is a premiere luxury birthing centre offering mother and child care services.

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved

Granules India receives ANDA approval for Loperamide Hydrochloride and Simethicone Tablets

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)